BioArctic AB

Update in progress

BIOA-B.ST (Stockholm)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

BioArctic AB (publ) develops biological drugs for central nervous system disorders in Sweden. It conducts R&D on innovative biologics, including antibodies for high unmet medical needs, focusing on neurodegenerative diseases such as Alzheimer’s and Parkinson’s, and other CNS conditions. It owns a therapeutic monoclonal antibody platform and collaborates with Eisai and AbbVie. Lead programs include lecanemab in phase 3, Exidavnemab in phase 2, plus several preclinical and discovery candidates. Founded 2000, based in Stockholm; renamed from BioArctic Neuroscience AB in 2016.

Company score

Sentiment: 0.29; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.04; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.15; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive